Role of RUNX3 in bone morphogenetic protein signaling in colorectal cancer

Cancer Research

Volumn 70, Issue 10, 2010, Pages 4243-4252

  Lee, Cecilia Wei Lin ^a,b,c   Ito, Kosei ^d   Ito, Yoshiaki ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^d NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; SMAD4 PROTEIN; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR RUNX3;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; ONCOGENE C MYC; POLYPOSIS; PRIORITY JOURNAL;

APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; BONE MORPHOGENETIC PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COLORECTAL NEOPLASMS; CORE BINDING FACTOR ALPHA 3 SUBUNIT; HUMANS; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 77952869160     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3805     Document Type: Article

References (48)

1. Ito Y. RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv Cancer Res 2008;99:33-76. (Pubitemid 350148068)
2. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-129 (Pubitemid 32952643)
3. Hanai J, Chen LF, Kanno T, et al. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Cα promoter. J Biol Chem 1999;274:31577-31582 (Pubitemid 129501615)
4. Yano T, Ito K, Fukamachi H, et al. The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor β-induced apoptosis. Mol Cell Biol 2006;26:4474-4488 (Pubitemid 43877568)
5. Yamamura Y, Lee WL, Inoue K, Ida H, Ito Y. RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells. J Biol Chem 2006;281:5267-5276 (Pubitemid 43847791)
6. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002;109:113-124
7. Goel A, Arnold CN, Tassone P, et al. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer 2004;112:754-759 (Pubitemid 39435259)
8. Li QL, Kim HR, Kim WJ, et al. Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun 2004;314:223-228 (Pubitemid 38058391)
9. Lau QC, Raja E, Salto-Tellez M, et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 2006;66:6512-6520 (Pubitemid 44085605)
10. Ito K, Liu Q, Salto-Tellez M, et al. RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 2005;65:7743-7750 (Pubitemid 41297249)
11. Fujii S, Ito K, Ito Y, Ochiai A. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 2008;283:17324-17332
12. Kim WJ, Kim EJ, Jeong P, et al. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res 2005;65:9347-9354 (Pubitemid 41508002)
13. Bae SC, Takahashi E, Zhang YW, et al. Cloning, mapping and expression of PEBP2αC, a third gene encoding the mammalian Runt domain. Gene 1995;159:245-248
14. Ku JL, Kang SB, Shin YK, et al. Promoter hypermethylation down-regulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene 2004;23:6736-6742 (Pubitemid 39280005)
15. Ito K, Lim AC, Salto-Tellez M, et al. RUNX3 attenuates β-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 2008;14:226-237
16. ten Dijke P, Yamashita H, Sampath TK, et al. Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem 1994;269:16985-16988
17. Koenig BB, Cook JS, Wolsing DH, et al. Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells. Mol Cell Biol 1994;14:5961-5974 (Pubitemid 24264425)
18. Liu F, Ventura F, Doody J, Massague J. Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol Cell Biol 1995;15:3479-3486
19. Kleeff J, Maruyama H, Ishiwata T, et al. Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology 1999;116: 1202-1216 (Pubitemid 29203031)
20. Wen XZ, Akiyama Y, Baylin SB, Yuasa Y. Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene 2006;25:2666-2673
21. Howe JR, Roth S, Ringold JC, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998;280:1086-1088 (Pubitemid 28234951)
22. Howe JR, Bair JL, Sayed MG, et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 2001;28:184-187
23. Haramis AP, Begthel H, van den Born M, et al. De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. Science 2004;303:1684-1686
24. Oshima H, Itadani H, Kotani H, Taketo MM, Oshima M. Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling. Cancer Res 2009;69:2729-2733
25. He XC, Zhang J, Tong WG, et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-β-catenin signaling. Nat Genet 2004;36:1117-1121 (Pubitemid 41184475)
26. Beppu H, Mwizerwa ON, Beppu Y, et al. Stromal inactivation of BMPRII leads to colorectal epithelial overgrowth and polyp formation. Oncogene 2008;27:1063-1070 (Pubitemid 351253183)
27. Yagi K, Furuhashi M, Aoki H, et al. c-myc is a downstream target of the Smad pathway. J Biol Chem 2002;277:854-861 (Pubitemid 34952127)
28. Sierra J, Yoshida T, Joazeiro CA, Jones KA. The APC tumor suppressor counteracts β-catenin activation and H3K4 methylation at Wnt target genes. Genes Dev 2006;20:586-600. (Pubitemid 43345324)
29. Kawamura C, Kizaki M, Ikeda Y. Bone morphogenetic protein (BMP)-2 induces apoptosis in human myeloma cells. Leuk Lymphoma 2002; 43:635-639 (Pubitemid 34232935)
30. Hardwick JC, Van Den Brink GR, Bleuming SA, et al. Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology 2004;126:111-121
31. Massague J. TGF-β signal transduction. Annu Rev Biochem 1998; 67:753-791
32. Lee KS, Kim HJ, Li QL, et al. Runx2 is a common target of transforming growth factor β1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 2000;20:8783-8792
33. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997;275:1784-1787 (Pubitemid 27136714)
34. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-1512 (Pubitemid 28425575)
35. Sasaki T, Suzuki H, Yagi K, et al. Lymphoid enhancer factor 1 makes cells resistant to transforming growth factor β-induced repression of c-myc. Cancer Res 2003;63:801-806 (Pubitemid 36231979)
36. Wen XZ, Miyake S, Akiyama Y, Yuasa Y. BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. Biochem Biophys Res Commun 2004;316:100-106 (Pubitemid 38299134)
37. Katsuno Y, Hanyu A, Kanda H, et al. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 2008;27:6322-6333
38. Kang MH, Kim JS, Seo JE, Oh SC, Yoo YA. BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Exp Cell Res 316:24-37.
39. Ito Y, Miyazono K. RUNX transcription factors as key targets of TGF-β superfamily signaling. Curr Opin Genet Dev 2003;13:43-47 (Pubitemid 36143926)
40. Shi MJ, Stavnezer J. CBFα3 (AML2) is induced by TGF-β1 to bind and activate the mouse germline Igα promoter. J Immunol 1998; 161:6751-6760 (Pubitemid 28562218)
41. Phimphilai M, Zhao Z, Boules H, Roca H, Franceschi RT. BMP signaling is required for RUNX2-dependent induction of the osteoblast phenotype. J Bone Miner Res 2006;21:637-646
42. Pimanda JE, Donaldson IJ, de Bruijn MF, et al. The SCL transcriptional network and BMP signaling pathway interact to regulate RUNX1 activity. Proc Natl Acad Sci U S A 2007;104:840-845
43. Corzo C, Petzold M, Mayol X, et al. RxFISH karyotype and MYC amplification in the HT-29 colon adenocarcinoma cell line. Genes Chromosomes Cancer 2003;36:425-426 (Pubitemid 36314528)
44. Liu Z, Tang Y, Qiu T, Cao X, Clemens TL. A dishevelled-1/Smad1 interaction couples WNT and bone morphogenetic protein signaling pathways in uncommitted bone marrow stromal cells. J Biol Chem 2006;281:17156-17163 (Pubitemid 43909522)
45. Nishanian TG, Kim JS, Foxworth A, Waldman T. Suppression of tumorigenesis and activation of Wnt signaling by bone morphogenetic protein 4 in human cancer cells. Cancer Biol Ther 2004;3:667-675 (Pubitemid 41351107)
46. Sekiya T, Adachi S, Kohu K, et al. Identification of BMP and activin membrane-bound inhibitor (BAMBI), an inhibitor of transforming growth factor-β signaling, as a target of the β-catenin pathway in colorectal tumor cells. J Biol Chem 2004;279:6840-6846 (Pubitemid 38248826)
47. Kim JS, Crooks H, Dracheva T, et al. Oncogenic β-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. Cancer Res 2002;62:2744-2748 (Pubitemid 34525754)
48. Luppen CA, Chandler RL, Noh T, Mortlock DP, Frenkel B. BMP-2 vs. BMP-4 expression and activity in glucocorticoid-arrested MC3T3-E1 osteoblasts: Smad signaling, not alkaline phosphatase activity, predicts rescue of mineralization. Growth Factors 2008;26:226-237